Cell therapy weekly: US FDA places clinical hold on LentiGlobin gene therapy trials for sickle cell disease

This week: the US FDA has put a clinical hold on bluebird bio’s LentiGlobin gene therapy program for sickle cell disease, BrainStorm reports that the US FDA does not believe data from NurOwn supports a Biologics License Agreement, spinal cord injury patients demonstrate significant improvements in motor function in a preliminary study using autologous mesenchymal stem cells, and Bio-Techne signs a license agreement with Luminary Therapeutics for the use of TcBuster™ in the development of CAR-T therapies. The news highlights: US FDA places clinical hold on LentiGlobin gene therapy trials for sickle cell disease BrainStorm’s NurOwn data does not support...